180 Life Sciences Corp ATNF:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/24/24 EDT
1.82UNCH (UNCH)
Volume
16,110
52 week range
1.33 - 27.93
Loading...
  • Open1.93
  • Day High1.95
  • Day Low1.76
  • Prev Close1.82
  • 52 Week High27.93
  • 52 Week High Date05/19/23
  • 52 Week Low1.33
  • 52 Week Low Date04/16/24

Key Stats

  • Market Cap1.552M
  • Shares Out852,769.97
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-55.13

KEY STATS

  • Open1.93
  • Day High1.95
  • Day Low1.76
  • Prev Close1.82
  • 52 Week High27.93
  • 52 Week High Date05/19/23
  • 52 Week Low1.33
  • 52 Week Low Date04/16/24
  • Market Cap1.552M
  • Shares Out852,769.97
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change-55.13

RATIOS/PROFITABILITY

  • EPS (TTM)-64.01
  • P/E (TTM)-0.03
  • Fwd P/E (NTM)182.00
  • EBITDA (TTM)-13.372M
  • ROE (TTM)-355.47%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-825.23%

EVENTS

  • Earnings Date05/19/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On 180 Life Sciences Corp

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor...
James Woody M.D., Ph.D.
Chief Executive Officer, Director
Ozan Pamir
Chief Financial Officer, Company Secretary
Address
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto, CA
94306
United States